AbCellera is clinical-stage biotech company focused developing antibody-based medicines in the areas of endocrinology, women’s health, immunology and oncology
Attend our talk at IMS 2026 to see top-line Phase 2 results on ABCL635, an investigational, potential best-in-class antibody drug for the non-hormonal treatment of vasomotor symptoms.
Read more about ABCL635 here:
#IMSRio2026# #IMS2026#